RGLS Form 4: $7 Cash-Plus-CVR Deal Finalized, Insider Ownership Now Zero
Rhea-AI Filing Summary
Form 4 overview: On 06/25/2025 Preston Klassen, President, Head of R&D and Director of Regulus Therapeutics Inc. (RGLS), reported the disposition of all his equity holdings following the closing of the merger with Novartis AG.
Under the Agreement and Plan of Merger signed 04/29/2025, Novartis’ wholly-owned Redwood Merger Sub acquired every outstanding Regulus common share. Each share was converted into the right to receive (i) US$7.00 in cash and (ii) one contingent value right (CVR) that pays an additional US$7.00 in cash if a specified milestone is met.
The filing lists the cancellation and cash-plus-CVR conversion of 115,555 common shares and 1,898,000 in-the-money stock options with exercise prices between US$1.00 and US$2.01. Following these transactions, Klassen now reports zero beneficial ownership of Regulus equity.
The Form 4 therefore confirms: (1) the merger became effective on 06/25/2025; (2) insiders have exited their positions at the agreed consideration; and (3) Regulus is now a wholly-owned subsidiary of Novartis. No earnings data or ongoing share ownership remain for public investors, shifting future value to the privately held CVRs.
Positive
- Merger consummation confirmed: Insider filing verifies 06/25/2025 closing of Novartis acquisition at $7 cash plus one CVR per share.
Negative
- None.
Insights
TL;DR: Filing confirms merger close; insider equity converted to $7 cash + CVR—positive exit for shareholders.
The Form 4 is procedural but significant. It verifies that Novartis completed the cash tender offer and downstream merger on 06/25/2025, eliminating the public equity float. The $7.00 cash price represents the definitive payout; the attached CVR offers a separate, milestone-dependent upside of another $7.00. Insider positions, including nearly 1.9 million options, were cashed out and canceled—standard treatment that prevents option overhang for Novartis. For former RGLS shareholders this affirms receipt of consideration and shifts remaining exposure to CVR milestone risk. No adverse terms or post-closing adjustments are disclosed. Impact is positive but mostly confirms previously announced terms rather than introducing new valuation drivers.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option | 350,000 | $0.00 | -- |
| Disposition | Stock Option | 225,000 | $0.00 | -- |
| Disposition | Stock Option | 120,000 | $0.00 | -- |
| Disposition | Stock Option | 528,000 | $0.00 | -- |
| Disposition | Stock Option | 675,000 | $0.00 | -- |
| Disposition | Common Stock | 115,555 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, (i) each Share was converted into the right to receive the Offer Price and (ii) each performance stock unit ("PSU") was canceled and converted into the right to receive (A) an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of Shares underlying such PSU immediately prior to the Effective Time by (y) the Closing Amount plus (B) one CVR with respect to each such Share subject to such PSU immediately prior to the Effective Time. The 67,500 PSUs reported herein were unintentionally omitted from previous Form 4 filings made by the Reporting Person following the achievement of the performance-based vesting conditions applicable thereto. Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
